Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Signs and Symptoms 1Psoriasis 1Nutrition Disorders 1Insulin Resistance 1Inflammatory Bowel Diseases 1Glioma 1Glioblastoma 1Gastroparesis 1Feeding and Eating Disorders 1Esophageal Neoplasms 1Dumping Syndrome 1Diarrhea 1Breast Neoplasms 1Brain Neoplasms 1Arthritis, Rheumatoid 1

Interventions

Infliximab 3Tea 2Polyethylene Glycols 2Lidocaine 2Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2sodium phosphate 1purine 1prucalopride 1picosulfate sodium 1golimumab 1fumaric acid 1Sulfasalazine 1Pneumococcal Vaccines 1Passive Cutaneous Anaphylaxis 1Papillomavirus Vaccines 1Narrow Band Imaging 1Morphine 1Methotrexate 1Mesalamine 1Mercaptopurine 1MEDI2070 1Exercise 1Etanercept 1Dietary Supplements 1Diatrizoate Meglumine 1Diagnostic Imaging 1Calcium Dobesilate 1CT-P13 1Bupivacaine 1Bisacodyl 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Inflammatory Bowel Diseases × Sulfasalazine × Clear all
NCT02376478 2015-03-03

On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection

Medical University of Vienna

Completed
222 enrolled

Psoriasis, Inflammatory Bowel Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡